Skip to Content
Søk Menu

CLL: Needs At Least 10 Years of Follow-Up for Clinical Trials

Carsten Utoft Niemann, Consultant, PhD, Department of Hematology, Rigshospitalet, and Clinical Lecturer at the University of Copenhagen, presented highlights and Danish perspectives on CLL at the Danish Evening at EHA 2024.

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Relaterat innehåll

Several Trials Showed Improvements in the Treatment of Multiple Myeloma

/ BestPractice Nordic
EHA24Myelom

EHA 2024: One of the Most Important for Many Years

/ BestPractice Nordic
EHA24Lymfom

The Development of New Treatment Options within AML Is Slower Than in Other Disease Areas within Hematology

/ BestPractice Nordic
AMLEHA24

New Data from EHA Shared and Discussed at Danish Evening

/ Jan Andreasen
EHA24
Maria Eugenia Chollet

Promising Avenues for the Development of Personalized Treatment for FVII Deficiency

/ Maria Eugenia Chollet
EHA24 Play the Video 5:06
Hanne Norseth

Vaccinating Against Mutated RAS in Multiple Myeloma

/ Hanne Norseth
EHA24Myelom Play the Video 3:27
Sergio Martinez Høyer

An Excellent Target with a Wide Therapeutic Window in del(5q) Myeloid Malignancies

/ Sergio Martinez Høyer
EHA24 Play the Video 5:13
Frida Bugge Askeland

Treating MRD Relapse After First-Line Treatment May Prolong PFS and OS in Myeloma Patients

/ Frida Bugge Askeland
EHA24Myelom Play the Video 1:59
Sigrid S. Skånland

From Genomic Precision Medicine to Functional Precision Medicine in Hematology

/ Sigrid S. Skånland
EHA24 Play the Video 02:51
Back to top